Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
U.S. FDA approves third indication of darolutamide for prostate cancer
Details : Nubeqa (darolutamide) is an orally available androgen receptor inhibitors, which is currently being evaluated for the treatment of metastatic hormone-sensitive prostate cancer.
Product Name : Nubeqa
Product Type : HPAPI
Upfront Cash : Inapplicable
June 03, 2025
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Invenra
Deal Size : Undisclosed
Deal Type : Agreement
Orion, Invenra Sign Deal for Bispecific Antibody Cancer Therapeutics
Details : Under the terms of the agreements, Invenra will leverage its B-Body bispecific antibody platform from monoclonal antibody discovery to treat cancer.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
January 30, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Invenra
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Orion's Partner Bayer Submits Darolutamide Application in China for Third Indication
Details : Nubeqa (darolutamide) is an orally available androgen receptor inhibitors, which is currently being evaluated for the treatment of metastatic hormone-sensitive prostate cancer.
Product Name : Nubeqa
Product Type : HPAPI
Upfront Cash : Inapplicable
January 07, 2025
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Orion's Partner Bayer Submits Darolutamide Application in EU for Third Indication
Details : Nubeqa (darolutamide) is an orally available androgen receptor inhibitors, which is currently being evaluated for the treatment of metastatic hormone-sensitive prostate cancer.
Product Name : Nubeqa
Product Type : HPAPI
Upfront Cash : Inapplicable
October 14, 2024
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Bayer Seeks U.S. FDA Nod for Third Indication of Orion-Originated Darolutamide
Details : Nubeqa (darolutamide) is an orally available androgen receptor inhibitors, which is currently being evaluated for the treatment of metastatic hormone-sensitive prostate cancer.
Product Name : Nubeqa
Product Type : HPAPI
Upfront Cash : Inapplicable
September 26, 2024
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase III ARANOTE Trial in Prostate Cancer Meets Primary Endpoint
Details : Nubeqa (darolutamide) is an orally available androgen receptor inhibitors, which is currently being evaluated for the treatment of metastatic hormone-sensitive prostate cancer.
Product Name : Nubeqa
Product Type : HPAPI
Upfront Cash : Inapplicable
July 17, 2024
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Opevesostat,Dexamethasone,Fludrocortisone Acetate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Orion and MSD Initiate Two Phase 3 Trials Of ODM-208 in Prostate Cancer
Details : ODM-208/MK5684, a CYP11A1 inhibitor, is in Phase 3 trials for metastatic castration-resistant prostate cancer with hormone replacement.
Product Name : ODM-208
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 01, 2024
Lead Product(s) : Opevesostat,Dexamethasone,Fludrocortisone Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Opevesostat,Dexamethasone,Fludrocortisone Acetate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Merck & Co
Deal Size : $1,920.0 million
Deal Type : Licensing Agreement
Merck and Orion Mutual Option Exercise for Opevesostat in Prostate Cancer Treatment
Details : Through the license agreement, Merck will gain global rights to develop and commercialize MK-5684 (opevesostat), which is being evaluated for metastatic castration-resistant prostate cancer.
Product Name : MK-5684
Product Type : Other Small Molecule
Upfront Cash : $290.0 million
January 07, 2024
Lead Product(s) : Opevesostat,Dexamethasone,Fludrocortisone Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Merck & Co
Deal Size : $1,920.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Opevesostat,Dexamethasone,Hydrocortisone
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov Database
Details : ODM-208 (or MK-5684) is an investigational oral, non-steroidal and selective inhibitor of the CYP11A1 enzyme discovered and developed by Orion for the treatment of hormone-dependent cancers, such as metastatic castration-resistant prostate cancer.
Product Name : ODM-208
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 21, 2023
Lead Product(s) : Opevesostat,Dexamethasone,Hydrocortisone
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darolutamide,Docetaxel
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Orion and Bayer Expand Clinical Development Program for Darolutamide in Prostate Cancer
Details : Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of pros...
Product Name : Nubeqa
Product Type : HPAPI
Upfront Cash : Inapplicable
March 23, 2023
Lead Product(s) : Darolutamide,Docetaxel
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
